Business Context and Reporting Period
This Form 8-K Current Report was filed by AnaptysBio, Inc. on August 22, 2017. The registrant is a Delaware corporation headquartered in San Diego, California, and is designated as an emerging growth company. The report primarily addresses corporate governance changes rather than operational or financial performance updates.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and does not contain financial statements or operational metrics.
Material Changes
- Board Appointment: Effective August 22, 2017, the Board of Directors elected J. Anthony Ware, M.D. to fill a vacancy as a Class II director.
- Term: Dr. Ware's term expires at the 2019 Annual Meeting of stockholders.
- Independence: The Board determined Dr. Ware qualifies as an independent director under the Securities Act of 1933 and NASDAQ listing standards.
- Compensation: Dr. Ware will receive compensation per the standard non-employee director policy, including a pro-rated annual cash retainer and option grants for the remainder of 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, financial guidance, or specific risk factors. It notes that there are no arrangements or understandings regarding Dr. Ware's selection and no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K. An indemnity agreement was executed effective on the date of appointment.
Investor Verification Checklist
- Verify Dr. Ware's professional background and qualifications as an independent director.
- Review the standard non-employee director compensation policy to understand the specific value of the pro-rated retainer and option grants.
- Check the attached Exhibit 99.01 (Press Release dated August 24, 2017) for additional context on the appointment.
- Confirm the impact of this appointment on the composition of the Board's committees, if applicable.